The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.
 
Davendra Sohal
Honoraria - Foundation Medicine
Consulting or Advisory Role - Perthera
Research Funding - Agios (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Novartis (Inst); OncoMed (Inst)
Travel, Accommodations, Expenses - Foundation Medicine
 
Danika L. Lew
No Relationships to Disclose
 
Syed A. Ahmad
No Relationships to Disclose
 
Namita Gandhi
No Relationships to Disclose
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Boston Biomedical; Celgene; Genentech/Roche; Guardant Health; Ipsen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Ipsen
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst)
 
Andrea Wang-Gillam
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Jacobio; Merrimack; Vicus Therapeutics
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); pfizer (Inst); Plexxikon (Inst); Precision Therapeutics (Inst); Roche (Inst); Verastem (Inst); Xcovery (Inst)
 
James Lloyd Wade
Employment - Johnson & Johnson (I)
Stock and Other Ownership Interests - Abbott (I); Celgene; GlaxoSmithKline (I); Johnson & Johnson (I); Novartis (I)
 
Katherine A Guthrie
No Relationships to Disclose
 
Andrew M. Lowy
Honoraria - Celgene
Consulting or Advisory Role - Halozyme; Merck; PFizer
Research Funding - Mitsubishi Tanabe Pharma; Syros Pharmaceuticals
Expert Testimony - Merck
Travel, Accommodations, Expenses - Pfizer
 
Philip Agop Philip
Honoraria - Amgen; ASLAN Pharmaceuticals; Bayer; Biologics; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Lexi Pharma; Merck; Novartis; Rafael Pharmaceuticals; Sanofi
Consulting or Advisory Role - Celgene; Halozyme; Ipsen; Merck; Merrimack; novartis; Rafael Pharmaceuticals
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Celgene; Ipsen; Merck
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); tyme (Inst); TYME (Inst)
Other Relationship - Halozyme
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Exelixis; Genentech